Search Results - "Mora, Joana L."

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis by Brastianos, Priscilla K., Lee, Eudocia Quant, Cohen, Justine V., Tolaney, Sara M., Lin, Nancy U., Wang, Nancy, Chukwueke, Ugonma, White, Michael D., Nayyar, Naema, Kim, Albert, Alvarez-Breckenridge, Christopher, Krop, Ian, Mahar, Maura Keeley, Bertalan, Mia S., Shaw, Brian, Mora, Joana L., Goss, Nathaniel, Subramanian, Megha, Nayak, Lakshmi, Dietrich, Jorg, Forst, Deborah A., Nahed, Brian V., Batchelor, Tracy T., Shih, Helen A., Gerstner, Elizabeth R., Moy, Beverly, Lawrence, Donald, Giobbie-Hurder, Anita, Carter, Scott L., Oh, Kevin, Cahill, Daniel P., Sullivan, Ryan J.

“…An increasing fraction of patients with metastatic cancer develop leptomeningeal dissemination of disease (LMD), and survival is dismal 1 – 3 . We conducted a…”
Get full text

Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid by White, Michael D, Klein, Robert H, Shaw, Brian, Kim, Albert, Subramanian, Megha, Mora, Joana L, Giobbie-Hurder, Anita, Nagabhushan, Deepika, Jain, Aarushi, Singh, Mohini, Kuter, Benjamin M, Nayyar, Naema, Bertalan, Mia S, Stocking, Jackson H, Markson, Samuel C, Lastrapes, Matthew, Alvarez-Breckenridge, Christopher, Cahill, Daniel P, Gydush, Gregory, Rhoades, Justin, Rotem, Denisse, Adalsteinsson, Viktor A, Mahar, Maura, Kaplan, Alexander, Oh, Kevin, Sullivan, Ryan J, Gerstner, Elizabeth, Carter, Scott L, Brastianos, Priscilla K

“…Leptomeningeal disease (LMD) is a devastating complication of cancer that is frequently underdiagnosed owing to the low sensitivity of cerebrospinal fluid…”
Get full text

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis by Brastianos, Priscilla K., Lee, Eudocia Quant, Cohen, Justine V., Tolaney, Sara M., Lin, Nancy U., Wang, Nancy, Chukwueke, Ugonma, White, Michael D., Nayyar, Naema, Kim, Albert, Alvarez-Breckenridge, Christopher, Krop, Ian, Mahar, Maura Keeley, Bertalan, Mia S., Shaw, Brian, Mora, Joana L., Goss, Nathaniel, Subramanian, Megha, Nayak, Lakshmi, Dietrich, Jorg, Forst, Deborah A., Nahed, Brian V., Batchelor, Tracy T., Shih, Helen A., Gerstner, Elizabeth R., Moy, Beverly, Lawrence, Donald, Giobbie-Hurder, Anita, Carter, Scott L., Oh, Kevin, Cahill, Daniel P., Sullivan, Ryan J.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis by Brastianos, Priscilla K., Strickland, Matthew R., Lee, Eudocia Quant, Wang, Nancy, Cohen, Justine V., Chukwueke, Ugonma, Forst, Deborah Anne, Eichler, April, Overmoyer, Beth, Lin, Nancy U., Chen, Wendy Y., Bardia, Aditya, Juric, Dejan, Dagogo-Jack, Ibiayi, White, Michael D., Dietrich, Jorg, Nayyar, Naema, Kim, Albert E., Alvarez-Breckenridge, Christopher, Mahar, Maura, Mora, Joana L., Nahed, Brian V., Jones, Pamela S., Shih, Helen A., Gerstner, Elizabeth R., Giobbie-Hurder, Anita, Carter, Scott L., Oh, Kevin, Cahill, Daniel P., Sullivan, Ryan J.

“…Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with a poor prognosis and limited treatment options. We present a single…”
Get full text

Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases by Prakadan, Sanjay M., Alvarez-Breckenridge, Christopher A., Markson, Samuel C., Kim, Albert E., Klein, Robert H., Nayyar, Naema, Navia, Andrew W., Kuter, Benjamin M., Kolb, Kellie E., Bihun, Ivanna, Mora, Joana L., Bertalan, Mia Solana, Shaw, Brian, White, Michael, Kaplan, Alexander, Stocking, Jackson H., Wadsworth, Marc H., Lee, Eudocia Q., Chukwueke, Ugonma, Wang, Nancy, Subramanian, Megha, Rotem, Denisse, Cahill, Daniel P., Adalsteinsson, Viktor A., Miller, Jeffrey W., Sullivan, Ryan J., Carter, Scott L., Brastianos, Priscilla K., Shalek, Alex K.

“…Leptomeningeal disease (LMD) is a devastating complication of solid tumor malignancies, with dire prognosis and no effective systemic treatment options. Over…”
Get full text

Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition by Alvarez-Breckenridge, Christopher, Markson, Samuel C, Stocking, Jackson H, Nayyar, Naema, Lastrapes, Matt, Strickland, Matthew R, Kim, Albert E, de Sauvage, Magali, Dahal, Ashish, Larson, Juliana M, Mora, Joana L, Navia, Andrew W, Klein, Robert H, Kuter, Benjamin M, Gill, Corey M, Bertalan, Mia, Shaw, Brian, Kaplan, Alexander, Subramanian, Megha, Jain, Aarushi, Kumar, Swaminathan, Danish, Husain, White, Michael, Shahid, Osmaan, Pauken, Kristen E, Miller, Brian C, Frederick, Dennie T, Hebert, Christine, Shaw, McKenzie, Martinez-Lage, Maria, Frosch, Matthew, Wang, Nancy, Gerstner, Elizabeth, Nahed, Brian V, Curry, William T, Carter, Bob, Cahill, Daniel P, Boland, Genevieve Marie, Izar, Benjamin, Davies, Michael A, Sharpe, Arlene H, Suvà, Mario L, Sullivan, Ryan J, Brastianos, Priscilla K, Carter, Scott L

“…Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease…”
Get more information

Author Correction: Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases by Prakadan, Sanjay M., Alvarez-Breckenridge, Christopher A., Markson, Samuel C., Kim, Albert E., Klein, Robert H., Nayyar, Naema, Navia, Andrew W., Kuter, Benjamin M., Kolb, Kellie E., Bihun, Ivanna, Mora, Joana L., Bertalan, Mia Solana, Shaw, Brian, White, Michael, Kaplan, Alexander, Stocking, Jackson H., Wadsworth, Marc H., Lee, Eudocia Q., Chukwueke, Ugonma, Wang, Nancy, Subramanian, Megha, Rotem, Denisse, Cahill, Daniel P., Adalsteinsson, Viktor A., Miller, Jeffrey W., Sullivan, Ryan J., Carter, Scott L., Brastianos, Priscilla K., Shalek, Alex K.

Get full text